Prevents bronchospasm. ANDA 207628, held by Luoxin Aurovitas. Levalbuterol Hydrochloride.
As of Nov 16, 2026, ANDA 207628 (Levalbuterol Hydrochloride), held by Luoxin Aurovitas, was first approved by FDA on Jan 31, 2017, with 1 approved supplement and 0 published complete response letters.
Levalbuterol inhalation solution (concentrate) is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution (concentrate) is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 31, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levalbuterol HydrochlorideEQ 0.25% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Feb 7, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 31, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters